Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

Publication

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

Journal Paper/Review - Mar 1, 2023

Meier Stephanie, Willemse Eline A J, Schaedelin Sabine A, Oechtering Johanna, Lorscheider Johannes, Melie-Garcia Lester, Cagol Alessandro, Barakovic Muhamed, Galbusera Riccardo, Subramaniam Suvitha, Barro Christian, Abdelhak Ahmed, Thebault Simon, Achtnichts Lutz, Lalive Patrice H, Müller Stefanie, Pot Caroline, Salmen Anke, Giulio Disanto, Zecca Chiara, D'Souza Marcus, Orleth Annette, Khalil Michael, Buchmann Arabella, Du Pasquier Renaud A, Yaldizli Ozgür, Derfuss Tobias, Berger Klaus, Hermesdorf Marco, Wiendl Heinz, Piehl Fredrik, Battaglini Marco, Fischer Urs, Kappos Ludwig, Gobbi Claudio, Granziera Cristina, Bridel Claire, Leppert David, Maceski Aleksandra Maleska, Benkert Pascal, Kuhle Jens

Citation

Meier S, Willemse E, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, Müller S, Pot C, Salmen A, Giulio D, Zecca C, D'Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli O, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maceski A, Benkert P, Kuhle J. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol 2023; 80:287-297.

Type

Journal Paper/Review (English)

Journal

JAMA Neurol 2023; 80

Publication Date

Mar 1, 2023

Issn Electronic

2168-6157

Pages

287-297

Brief description/objective

There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).